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We consider a mathematical model that describes the release of heparin-binding growth factors from
an affinity-based delivery system. In the delivery system, heparin binds to a peptide which has been
covalently cross-linked to a fibrin matrix. Growth factor in turn binds to the heparin, and growth factor
release is governed by both binding and diffusion mechanisms, the purpose of the binding being to slow
growth factor release. The governing mathematical model, which in its original formulation consists of
five partial differential equations, is reduced to a system of just two equations. We identify the governing
non-dimensional parameters that can be varied to tune the growth factor release rate. In particular, we
identify a parameter regime that ensures slow passive release (usually desirable) of at least a fraction of
the growth factor. It is found that slow release is assured if the matrix is prepared with the concentration of
cross-linked peptide greatly exceeding the dissociation constant of heparin from the peptide, and with the
concentration of heparin greatly exceeding the dissociation constant of the growth factor from heparin.
Also, for the first time, in vitro experimental release data is directly compared with theoretical release
profiles generated by the model. We propose that the two stage release behaviour frequently seen in
experiments is due to an initial rapid out-diffusion of free growth factor over a diffusion time scale
(typically days), followed by a much slower release of the bound fraction over a time scale depending on
both diffusion and binding parameters (frequently months).
Keywords: drug delivery; heparin-binding growth factor; mathematical model.
1. Introduction
Background
In verterbrates, the extracellular matrix is a complex mixture of carbohydrates, proteins, and possi-
bly minerals, that surrounds the cells that form tissues (Alberts et al. (2002)). The extracellular matrix
helps cells to bind together, and regulates a number of cellular functions, such as differentiation, pro-
liferation, migration, and adhesion. The matrix can achieve such regulation via the appropriate release
of growth factors, for which it can act as a depot. Macromolecules within the structure of the matrix
can bind growth factors with high affinity, enabling the matrix to serve as a growth factor reservoir. In
response to changes in local physiological conditions (such as the occurrence of a wound, for example),
cells may secrete enzymes that can release such growth factor depots from the matrix. This natural
growth factor release mechanism has inspired the design of affinity-based drug delivery systems that
mimic the retentive and protective properties of the extracellular matrix for growth factor. In this paper,
we analyze a mathematical model that describes drug release from some such delivery systems, make
recommendations as to how delivery system should be prepared, and, for the first time, compare the
predictions of the model directly with experimental data.
The extracellular matrix consists predominantly of two classes of macromolecules: glycosamino-
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glycans, and fibrous proteins, such as collagen and fibronectin. Glycosaminoglycans are polysaccharide
polymers that typically have a repeating unit consisting of two sugars. Heparin is glycosaminoglycan of
the matrix that is known to bind with a number growth factors in vivo via electrostatic interactions, ex-
amples being basic fibroblast growth factor (bFGF), nerve growth factor (NGF), neurotrophin-3 (NT-3),
and vascular endothelial growth factor (VEGF).
Affinity-based drug delivery systems
Sakiyama-Elbert & Hubbell (2000a) have developed a growth factor delivery system for wound
healing that exploits heparin’s ability to bind electrostatically with growth factor. The various elements
of their system are depicted schematically in Figure 1. The natural blood clotting matrix, fibrin, was
chosen as the base material. Three dimensional fibrin hydrogel scaffolds were fabricated, into which
invading cells could infiltrate, and release (via enzymatic processes) growth factor attached to the fibrin
matrix. The growth factor attaches to the matrix via a bi-domain peptide bound to heparin, as we now
explain. The peptide contains a domain which covalently cross-links to the fibrin matrix. However,
the peptide also contains a domain that can bind to heparin, and such bound heparin can in turn bind
to heparin-binding growth factor. Hence, growth factor attachment to the matrix is dependent on three
distinct interactions, which we crudely represent by: (fibrin)–(peptide)–(heparin)–(growth factor).
Fibrin matrix
Free growth factor (G)
Free heparin (H)
Immobilized peptide (P)
Growth factor-
- heparin complex (GH)
Heparin- peptide complex (HP)
Growth factor- heparin-
-peptide complex (GHP)
FIG. 1. A schematic representation of the fibrin matrix containing all six species of the model.
The peptide is susceptible to cleavage by enzymes released from invading cells. Cells infiltrate the
scaffold, release enzymes that degrade the peptide, and thereby release growth factor. In these systems,
it is desirable that the growth factor be retained by the matrix until such time as it is actively released by
cells. However, there inevitably will be some passive release, whereby free growth factor diffuses out of
the system before cells have had the oppurtunity to actively release it. Growth factor binding to heparin
is reversible, and it will not be permanently fixed to the matrix even in the absence of cells. The passive
release of growth factor is usually undesirable, and in this study we use a mathematical model proposed
by Sakiyama-Elbert & Hubbell (2000a) to help identify conditions that minimize it.
In Sakiyama-Elbert & Hubbell (2000a), the system was used to deliver the growth factor bFGF.
Specifically, they carried out experiments in which they placed dorsal root ganglia from chickens in
fibrin matrices loaded with bFGF. The purpose of their experiments was to evaluate the effect of the
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delivery system on neurite extension from the dorsal root ganglia. Their results demonstrated that the
delivery system could enhance neurite extension by up to about 100% relative to unmodified fibrin.
In subsequent studies, the system has been used to deliver NGF (Sakiyama-Elbert & Hubbell (2000b)
and Wood et al. (2007, 2009)), NT-3 (Taylor et al. (2004) and Willerth et al. (2008)), glial-derived neu-
rotrophic growth factor (GDNF) (Wood et al. (2008, 2009)), platelet-derived growth factor (PDGF)
(Willerth et al. (2008)), and sonic hedgehog (Willerth et al. (2008)). In Wood et al. (2009), a 13 mm
gap in a rat sciatic nerve was repaired using a silicone nerve guidance conduit containing the delivery
system loaded with GDNF; a schematic representation of such a conduit is given in Figure 2.
Fibrin MatrixNerve Conduit
Nerve Nerve
Peptide (   ),  Heparin (     )
and Growth Factor (  )
FIG. 2. A schematic representation of a nerve guidance conduit containing the growth factor delivery system.
Matrix preparation
We identify which elements of the delivery system may be varied to tune growth factor release by
briefly sketching how the fibrin matrices used in the above studies were prepared; see Sakiyama-Elbert & Hubbell
(2000a) for the technical details and references. A fibrinogen solution was prepared by mixing the
following components in appropriate quantity to achieve desired concentrations: plasminogen-free fib-
rinogen from pooled human plasma, calcium ions, thrombin, peptide, heparin, and growth factor. This
polymerization mixture was placed in a well of a 24-well tissue culture plate and was incubated un-
der appropriate conditions (Sakiyama-Elbert & Hubbell (2000a)) for an hour. It is clear then that the
concentrations of the peptide, heparin and growth factor in the polymerization mixture are easily var-
ied. However, a distinction needs to be made between the peptide that cross-links to the fibrin matrix
and the peptide that remains unbound in the gel since it is the cross-linked peptide only that forms
part of the delivery system. In Sakiyama et al. (1999) and Schense & Hubbell (1999), a procedure for
quantifying the fraction of peptide that cross-links to the matrix is described. If the unbound peptide in-
teracts significantly with the other free components of the system, then account must be taken of this in
the mathematical modelling, and in Wood et al. (2007) a quite large mathematical model incorporating
such effects is described. However, we do not incorporate free peptide in the model considered here for
reasons we shall discuss in Section 3.
The system is complex
Lin & Metters (2006) comments that the mathematical model proposed by Sakiyama-Elbert & Hubbell
(2000a) contains a relatively large number of parameters (we shall see that it has three diffusivities and
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four rate constants), and that this complicates their modelling approach. Indeed, the model in its origi-
nal formulation does contain six differential equations, three of which contain diffusion terms. A major
goal of the current study was to simplify the governing mathematical model. We shall show that under
conditions of typical interest, the model can be reduced to a standard system of just two coupled partial
differential equations governing the evolution of the concentrations of the total growth factor and total
heparin. We shall further show that under typical conditions, the release behaviour is dominated by the
values of just two non-dimensional parameters: the ratio of the concentration of cross-linked peptide to
the dissociation constant of heparin from peptide, and the ratio of the initial concentration of heparin
to the dissociation constant of the growth factor from heparin. Lin further comments that theoretical
profiles generated by the model had yet to be directly compared with experimental data. We address
this issue in Section 4.
2. Mathematical modelling
2.1 Model equations
The mathematical model which we shall now describe was first developed by Sakiyama-Elbert & Hubbell
(2000a). There are six species in all in the model and, following Sakiyama-Elbert & Hubbell (2000a),
we use the following notation:
P is an immobile peptide covalently fixed to the fibrin matrix;
H is a mobile free heparin molecule that can diffuse through the fibrin matrix;
G is a mobile free growth factor molecule that can diffuse through the fibrin matrix;
GH is a mobile growth factor-heparin complex that can diffuse through the fibrin matrix;
HP is an immobile heparin-peptide complex fixed to the fibrin matrix;
GHP is an immobile growth factor-heparin-peptide complex fixed to the fibrin matrix.
In Figure 1, we schematically represent all six species in the matrix. The possible interactions between
these various species are described by the following four chemical reactions:
G+H
kf
⇋
kr
GH G+HP
kf
⇋
kr
GHP
(2.1)
H +P
KF
⇋
KR
HP GH +P
KF
⇋
KR
GHP
where k f ,kr,κF ,κR are the rate constants as shown. The first reaction, for example, represents the
reversible binding of a free growth factor molecule to a free heparin molecule, with association and
dissociation rate constants k f and kr, respectively. The other three reactions are similarly interpreted;
see Figure 1. It is noteworthy that we have assumed that the rate constants for the first and second
reactions above are the same, and similarly for the third and fourth reactions. This implies that we are
assuming that the association/dissociation behaviour of growth factor for heparin does not depend on
whether the heparin is free or bound to peptide; a similar comment applies to the binding heparin to
peptide.
The problems that are considered in this paper are one-dimensional, and throughout we shall denote
the spatial variable by x and the time variable by t. Following the notation of Sakiyama-Elbert & Hubbell
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(2000a), we denote by cG(x, t) the concentration of free growth factor G at location x and time t; the no-
tation for the concentrations of the other five species follows in an obvious fashion. In view of the
chemical reactions (2.1), and our assumptions regarding the mobility of the various species, the govern-
ing equations for the six concentrations take the form:
∂cG
∂ t = DG
∂ 2cG
∂x2 − k f cGcH + krcGH− k f cGcHP + krcGHP,
∂cH
∂ t = DH
∂ 2cH
∂x2 − k f cGcH + krcGH− KFcHcP + KRcHP,
∂cGH
∂ t = DGH
∂ 2cGH
∂x2 + k f cGcH− krcGH− KFcGHcP + KRcGHP, (2.2)
∂cP
∂ t =−KFcHcP + KRcHP− KFcGHcP + KRcGHP,
∂cHP
∂ t =−k f cGcHP + krcGHP + KFcHcP− KRcHP,
∂cGHP
∂ t = k f cGcHP− krcGHP + KFcGHcP− KRcGHP,
where DG, DH and DGH are the diffusivities for the free growth factor, free heparin, and free growth
factor-heparin complex, respectively; the species P, HP and GHP are taken to be immobile since the
peptide is assumed to be covalently fixed to the fibrin matrix, and consequently the equations for their
concentrations do not contain diffusion terms.
2.2 Boundary and initial conditions
We choose simple boundary conditions for (2.2) that allow direct comparison with available experimen-
x=0
x=L
Medium
Fibrin matrix
FIG. 3. A schematic depiction of the experimental setup for the release of growth factor from the fibrin matrix.
tal and theoretical results for growth factor release from the delivery system. We suppose that the fibrin
matrix occupies 06 x6 L, with x = 0 giving the location of a container wall through which the growth
factor cannot penetrate, and x = L denoting the interface between the matrix and an external medium
into which growth factor releases; see Figure 3. At the container wall, we impose no-flux conditions for
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the mobile species, so that:
∂cG
∂x = 0,
∂cH
∂x = 0,
∂cGH
∂x = 0 on x = 0. (2.3)
At the interface between the matrix and the external medium, we impose perfect sink conditions for the
mobile species:
cG = 0, cH = 0, cGH = 0 on x = L. (2.4)
The boundary conditions (2.3), (2.4) could also model in-vitro growth factor release from a nerve guide
tube (Sakiyama-Elbert & Hubbell (2000a)) occupying −L 6 x6 L, with x = ±L giving the location of
the ends of the tube; see Figure 2. In this context, (2.3) are interpreted as symmetry conditions on the
centre-line of the tube.
Equations (2.2) are solved subject to the following initial conditions:
cG = c
0
G, cH = c
0
H, cGH = 0, cP = c0P, cHP = 0, cGHP = 0 at t = 0, (2.5)
where c0G,c0H,c0P denote the initial concentrations of growth factor, heparin, and peptide, respectively,
in the polymerization mixture. In our modelling, we make the simplifying assumption that all of the
peptide in the polymerization mixture crosslinks covalently to the fibrin matrix. This is not likely to
occur in practice, but we shall show in Section 3 how our results may be modified to take account of the
presence of free peptide in the matrix. It should also be noted that free peptide will typically clear the
system over a period of a few days. We conclude this section by emphasising that the key results of this
paper are quite general for the model under typical conditions, and are not strongly dependent on the
particular choice of boundary and initial conditions made.
The mathematical model is now complete, and consists of equations (2.2), (2.3), (2.4), (2.5).
2.3 Model reduction
We now show how the model may frequently be reduced to a coupled pair of partial differential equa-
tions.
2.3.1 Non-dimensionalisation Before giving the non-dimensionalisation, we first note that (2.2) may
be written in the following equivalent form:
∂
∂ t (cG + cGH + cGHP) = DG
∂ 2cG
∂x2 +DGH
∂ 2cGH
∂x2 ,
∂
∂ t (cH + cGH + cHP + cGHP) = DH
∂ 2cH
∂x2 +DGH
∂ 2cGH
∂x2 ,
∂
∂ t (cGH + cGHP) = DGH
∂ 2cGH
∂x2 + k f cG(cH + cHP)− kr(cGH + cGHP), (2.6)
∂
∂ t (cHP + cGHP) = KFcP (cH + cGH)− KR (cHP + cGHP) ,
∂cGHP
∂ t = k f cGcHP + KFcGHcP− (kr + KR)cGHP,
cP + cHP + cGHP = c
0
P,
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where, for example, equation (2.6)6 is obtained by forming (2.2)4+ (2.2)5+ (2.2)6. We denote the total
concentrations of growth factor and heparin in the matrix by cTG and cTH, respectively, so that:
cTG = cG + cGH + cGHP, c
T
H = cH + cGH + cHP + cGHP. (2.7)
Equations (2.6)1 and (2.6)2 give the evolution equations for the total growth factor and heparin, and may
be written in conservation form as:
∂cTG
∂ t +
∂ jTG
∂x = 0,
∂cTH
∂ t +
∂ jTH
∂x = 0, (2.8)
where
jTG =−DG
∂cG
∂x −DGH
∂cGH
∂x , j
T
H =−DH
∂cH
∂x −DGH
∂cGH
∂x , (2.9)
give the total flux of growth factor and heparin, respectively.
We introduce non-dimensional variables as follows:
x¯ =
x
L
, ¯t =
t
(L2/DGH)
, c¯G =
cG
c0G
, c¯H =
cH
c0H
, c¯P =
cP
c0P
, c¯GH =
cGH
c0G
,
c¯GHP =
cGHP
c0G
, c¯HP =
cHP
c0H
, c¯TG =
cTG
c0G
, c¯TH =
cTH
c0H
, ¯jTG =
jTG
(DGHc0G/L)
, ¯jTH =
jTH
(DGHc0H/L)
,
to obtain the following non-dimensional form for the governing initial boundary value problem (upon
dropping over-bars):
∂
∂ t (cG + cGH + cGHP) = D
∗
G
∂ 2cG
∂x2 +
∂ 2cGH
∂x2 ,
∂
∂ t (cH + cHP +(cGH + cGHP)/ηH/G) = D
∗
H
∂ 2cH
∂x2 +
1
ηH/G
∂ 2cGH
∂x2 ,
δG
∂
∂ t (cGH + cGHP) = δG
∂ 2cGH
∂x2 +KbHcG(cH + cHP)− (cGH + cGHP),
δH
∂
∂ t (ηH/GcHP + cGHP) = KbPcP (ηH/GcH + cGH)− (ηH/GcHP + cGHP) , (2.10)
δGδH
∂cGHP
∂ t = δH(KbHcGcHP− cGHP)+ δG(KbPcGHcP− cGHP),
cP +ηH/PcHP +
ηH/P
ηH/G
cGHP = 1,
∂cG
∂x = 0,
∂cH
∂x = 0,
∂cGH
∂x = 0 on x = 0,
cG = 0, cH = 0, cGH = 0 on x = 1,
cG = 1, cH = 1, cGH = 0, cP = 1, cHP = 0, cGHP = 0 at t = 0,
where:
D∗G =
DG
DGH
, D∗H =
DH
DGH
, ηH/G =
c0H
c0G
, ηH/P =
c0H
c0P
,
(2.11)
δG =
DGH
krL2
, δH =
DGH
KRL2
, KbH =
k f c0H
kr
, KbP =
KFc
0
P
KR
,
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are the governing non-dimensional parameters. The quantities KbH,KbP give a non-dimensional measure
of the strength of retention of growth factor by the heparin, and of heparin by the peptide, respectively.
We denote by
KDG-H =
kr
k f
, KDH-P =
KR
KF
,
the dissociation constants of growth factor from heparin, and of heparin from peptide, respectively, so
that:
KbH =
c0H
KDG-H
, KbP =
c0P
KDH-P
. (2.12)
It is noteworthy that KbH involves both the concentration of available binding sites for the growth factor
and the dissociation constant of growth factor from heparin. The case KbH ≫ 1 corresponds to the
growth factor being strongly retained by the heparin. Conversely, KbH ≪ 1 corresponds to weak retention
of growth factor by the heparin. The parameter KbP is similarly interpreted in the context of heparin
retention by the peptide.
The non-dimensional form for the total growth factor and heparin and their fluxes are given by:
cTG = cG + cGH + cGHP, c
T
H = cH + cHP +(cGH + cGHP)/ηH/G,
(2.13)
jTG =−D∗G
∂cG
∂x −
∂cGH
∂x , j
T
H =−D
∗
H
∂cH
∂x −
1
ηH/G
∂cGH
∂x .
2.3.2 Parameter values In Sakiyama-Elbert & Hubbell (2000a); Taylor et al. (2004); Willerth et al.
(2006, 2008) and Wood et al. (2007, 2008), the fibrin gels were prepared by placing 400 µ l of poly-
merization mixture in the wells of a 24-well plate. The diameter of each well in such a plate is 1.56
cm, from which it follows that the thickness of the gels was L≈ 0.2 cm. In Sakiyama-Elbert & Hubbell
(2000a), the heparin diffusivity was taken to be DH = 3.13× 10−5 cm2min−1, and for bFGF, the diffu-
sivities DG = 6.0× 10−5 cm2min−1 and DGH = 1.0× 10−5 cm2min−1 were used. These values, which
were based on the work of Saltzman et al. (1994) and Gaigalas et al. (1995), all have order of magnitude
10−5 cm2min−1. In Taylor et al. (2004), where the growth factor being considered was NT-3, the diffu-
sivities used were again of order 10−5 cm2min−1. Taking D = 3.0×10−5 cm2min−1 as a representative
diffusivity for a free species in the matrix and L = 0.2 cm, we calculate a typical diffusion time scale
for the system to be L2/D≈ 1 day. Hence, in a release experiment where the diffusivities are of order
10−5 cm2min−1, we would typically expect the unbound components to clear the system over a period
of some days, and this is consistent with the experimental results of Taylor et al. (2004) and Wood et al.
(2007, 2008).
There are also time scales associated with the rate constants for the chemical reactions (2.1), namely,
1/kr, 1/(k f c0H), 1/KR, and 1/(KFc0P). In Sakiyama-Elbert & Hubbell (2000a) and Taylor et al. (2004), the
values of the rate constants for the binding of heparin to the peptide were taken to be KR ≈ 80 min−1
and KF ≈ 109 M−1 min−1, and c0P was of order 10−4 M. For these values, we find that 1/KR ≈ 1 s,
1/(KFc0P) = 10−5 s, and we note that these times are tiny compared to the typical time scales associated
with diffusion (days), and furthermore, would remain so even if we made c0P orders of magnitude smaller.
For the binding of growth factor to heparin, the rate constants will depend on the nature of the growth
factor, and data is unfortunately frequently lacking. For bFGF, Sakiyama-Elbert & Hubbell (2000a) use
the values kr ≈ 1 min−1, k f ≈ 108 M−1 min−1, and take c0H ≈ 6× 10−5 M. For these values, 1/kr = 1
min and 1/(k f c0H)≈ 10−2 s, and these times are also small compared to the diffusion time scales.
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For NT-3, the k f and kr values are unknown, but Taylor et al. (2004) gives the approximation
KG-HD ≈ 10−6 M for the dissociation constant, which would imply that NT-3 has a low affinity for the
heparin binding site. By contrast, bFGF has a relatively high affinity for the heparin binding site, with
dissociation constant KG-HD ≈ 10−8 M. However, we shall show in this paper that, provided the govern-
ing mathematical model is appropriate, slow passive growth factor release is achieveable even for low
affinity binding of growth factor to heparin.
2.3.3 Reduction to a pair of coupled partial differential equations We conclude from the remarks
above that for many systems of practical interest, the time scales for the association and dissociation
rates in the chemical reactions (2.1) are much shorter than the diffusion time scales, so that we frequently
have:
L2
DG
,
L2
DH
,
L2
DGH
≫
1
kr
,
1
k f c0H
,
1
KR
,
1
KFc0P
.
In such cases, diffusion is rate limiting since it is the slowest process. We restrict our attention to such
systems in the current analysis. In terms of the dimensionless parameters (2.11), the conditions above
imply that δ G≪min(KbH,1) and δ H≪min(KbP,1), and so the differential equations (2.10)3, (2.10)4 and
(2.10)5 are replaced by the algebraic expressions:
KbHcG(cH + cHP) = cGH + cGHP, KbPcP (ηH/GcH + cGH) = ηH/GcHP + cGHP, (2.14)
θ (KbHcGcHP− cGHP)+KbPcGHcP− cGHP = 0,
where θ = δ H/δ G = kr/KR. The first two equations in (2.14) correspond to the equilibrium forms for the
binding of growth factor to heparin, and of heparin to peptide, respectively.
We solve the six algebraic expressions (2.10)6, (2.13)1, (2.14) for the concentrations of the six
species cG, cH, cGH, cP, cHP, cGHP in terms of the total concentration of growth factor, cTG, and heparin, cTH,
to obtain expressions of the form:
cG = cG(c
T
G,c
T
H), cP = cP(c
T
H), cGH = cGH(c
T
G,c
T
H), cGHP = cGHP(c
T
G,c
T
H),
cHP = cHP(c
T
G,c
T
H), cH = cH(c
T
G,c
T
H).
We do not display these expressions here, but they can be found in (A.1) of the Appendix. We note
that these formulae can be used to calculate the equilibrium concentrations for the various species prior
to release since both cTG and cTH are known at t = 0. A numerical calculation is not required to obtain
such quantities. In Figure 4, we plot curves for the equilibrium fraction of bound growth factor prior
to release using the formulae (A.1). We also note that it is sufficient to solve for cTG and cTH for t > 0 as
the concentrations for cG, cH, cGH, cP, cHP, cGHP then follow immediately from (A.1). This implies that we
can replace the problem containing five differential equations given by (2.10) by the following problem
containing just two coupled partial differential equations:
∂cTG
∂ t +
∂
∂x j
T
G(c
T
G,c
T
H,c
T
Gx,c
T
Hx) = 0,
∂cTH
∂ t +
∂
∂x j
T
H(c
T
G,c
T
H,c
T
Gx,c
T
Hx) = 0,
∂cTG
∂x = 0,
∂cTH
∂x = 0 on x = 0, (2.15)
cTG = 0, cTH = 0 on x = 1,
cTG = 1, cTH = 1 at t = 0,
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where
jTG(cTG,cTH,cTGx,cTHx) =−D∗G
∂
∂x cG(c
T
G,c
T
H)−
∂
∂x cGH(c
T
G,c
T
H),
jTH(cTG,cTH,cTGx,cTHx) =−D∗H
∂
∂x cH(c
T
G,c
T
H)−
1
ηH/G
∂
∂x cGH(c
T
G,c
T
H),
and where the expressions for cG(cTG,cTH) and cGH(cTG,cTH) are given in (A.1). We note that (2.15) is in a
standard form that can be readily given to a mathematical package such as MAPLE to solve.
3. Analysis and results
3.1 Optimal conditions for slow passive release: strongly retained heparin and growth factor
In a medical device such as a nerve guide tube, it is frequently required to maintain growth factor in the
device until such time as it is actively released by invading cells. In such cases, the device should be
designed so as to minimise passive release of growth factor via diffusion. There are five dimensionless
parameters that can in principle be independently varied in experiments to tune the system for a given
growth factor, and these are:
ηH/G =
c0H
c0G
, ηH/P =
c0H
c0P
, θ = kr
KR
, KbH =
c0H
KDG-H
, KbP =
c0P
KDH-P
.
We emphasise that the parameters KDH-P and κR are in principle tunable since peptides with desired proper-
ties can be designed (Wood et al. (2007)). However, if the peptide is also fixed, only three dimensionless
parameters can be independently varied in the experiments, one possible choice for these being ηH/G,ηH/P
and KbH. The parameters D∗G and D∗H cannot be changed in experiments as they are fixed for a given
growth factor. The parameters δG and δH are neglected here since they are typically tiny in systems of
interest.
In the literature to date, the emphasis has been on experimentally varying the parameters ηH/G and
ηH/P to determine optimal conditions for slow passive release; see Sakiyama-Elbert & Hubbell (2000a);
Taylor et al. (2004); Willerth et al. (2008) and Wood et al. (2007, 2008). In particular, experiments have
been carried out for very large values of the ratio ηH/G, and quite small values for the ratio ηH/P. However,
we now show that if one wishes to ensure slow passive release, then the key parameters to monitor are
KbH and KbP, rather than ηH/G and ηH/P. More precisely, we shall show that slow release of at least a
proportion of the growth factor is assured provided KbH,KbP ≫ 1 (with the other parameters being O(1),
although there are other possibilities), or, equivalently:
c0H ≫ KDG-H and c0P ≫ KDH-P. (3.1)
We recall that KbH,KbP ≫ 1 corresponds to strong retention of both growth factor by the heparin, and of
heparin by the peptide. Hence, if practicable, for slow release of growth factor, the matrix should usually
be prepared with the initial concentration of heparin being much larger than the dissociation constant of
growth factor from heparin, and the concentration of peptide covalently cross-linked to the fibrin matrix
peptide being much larger than the dissociation constant of heparin from peptide. We now justify this
conclusion using an asymptotic argument and by providing numerical evidence. In particular, we shall
demonstrate numerically that growth factor release can be relatively fast if the conditions (3.1) are not
met even with ηH/G ≫ 1 and ηH/P ≪ 1.
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3.1.1 Asymptotics: KbH,KbP ≫ 1 We write KbH = 1/ε , KbP = µ/ε and consider the limit ε → 0 in
(A.1) for fixed O(1) values of cTG and cTH, and with µ and all the remaining dimensionless parameters in
(A.1) being O(1). The fraction of bound drug in the matrix, which we denote by fB, is given by:
fB = cGHP
cG + cGH + cGHP
=
cGHP
cTG
;
some solutions for this quantity at t = 0 are displayed in Figure 4. For clarity, we revert to dimensional
quantities in this Section. In the limit ε → 0, we find that:
fB ∼


cTH
cTG
if cTH < cTG and cTH < c0P,
c0P
cTG
if cTH < cTG and cTH > c0P,
c0P
cTH
if cTH > cTG and cTH > c0P,
1 if cTH > cTG and cTH < c0P.
(3.2)
There are also three narrow transition regions at the interfaces of the four regimes listed above, but we
omit this detail since it does not contribute to the subsequent discussion. The results of (3.2) are readily
interpreted. Take, for example, the case fB ∼ 1 for cTH > cTG and cTH < c0P. Since in the current limit both the
growth factor and heparin are strongly retained, then provided there is enough heparin to accomodate
the growth factor (cTH > cTG) and enough peptide to accomodate the heparin (cTH < c0P), all of the growth
factor in the matrix will be bound to leading order ( fB ∼ 1). This is the desired regime for slow passive
release, as we now confirm. The other three cases are similarly interpreted.
To gain insight into the time it would take for the growth factor to passively release from the matrix,
we now consider the total flux of growth factor, jTG. We find as ε → 0 that:
jTG ∼


−DG
(
∂cTG
∂x −
c0G
c0H
∂cTH
∂x
)
if cTH < cTG and cTH < c0P,
−DG ∂c
T
G
∂x − (DGH−DG)
∂cTH
∂x if c
T
H < c
T
G and cTH > c0P,
−DGH
({
cTH−c
0
P
cTH
}
∂cTG
∂x +
c0Pc
T
G
cTH
2
∂cTH
∂x
)
if cTH > cTG and cTH > c0P,
−ε
(
A(cTG,cTH)
∂cTG
∂x +B(c
T
G,c
T
H)
∂cTH
∂x
)
if cTH > cTG and cTH < c0P,
(3.3)
where:
A(cTG,cTH) =
c0Hc
T
H
(cTG− c
T
H)
2 DG−
µc0P
cTH− c
0
P
DGH, B(cTG,c
T
H) =
µc0PcTG
(cTH− c
0
P)
2 DGH−
c0Hc
T
G
(cTG− c
T
H)
2 DG,
and assuming the dimensionless form for the derivatives arising are O(1). The point to note here is that
the flux of growth factor for the fourth regime, cTH > cTG and cTH < c0P, is O(ε) smaller than that for the
other three.
12 of 21 T. VO T.N. AND M.G. MEERE
10−5 10−4 10−3 10−2 10−1 100 101 102 103
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
etaH/P
In
it
ia
l 
fr
a
c
ti
o
n
 o
f 
b
o
u
n
d
 g
ro
w
th
 f
a
c
to
r
C0H < C
0
G
C0H > C
0
PC
0
G < C
0
H < C
0
P
10−2 10−1 100 101 102 103 104 105
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
etaH/G
In
it
ia
l 
fr
a
c
ti
o
n
 o
f 
b
o
u
n
d
 g
ro
w
th
 f
a
c
to
r
C0H > C
0
P
C0H < C
0
G C
0
G < C
0
H < C
0
P
FIG. 4. Theoretical curves for the equilibrium bound fraction of growth factor prior to release. The curves are calculated using
the formulae (A.1). In the figure on the left, ηH/P is varied and the remaining non-dimensional parameters are fixed. In the figure
on the right, ηH/G is varied with the other parameters fixed. The parameter values used are D∗G = 6, D∗H = 3, ηH/G/ηH/P = 2000,
θ = 9×10−3 , KbP = 3000 and KDG-H = 7.5×10−9M (Nugent & Edelman (1992)).
In view of (3.2) and (3.3), it is now clear that the optimal regime for slow passive release is cTH > cTG
and cTH < c0P, which indicates that the polymerization mixture for the matrix should have c0G < c0H < c0P.
Hence, we expand our original recommendations for matrix preparation, (3.1), to the following:
c0H ≫ KDG-H, c0P ≫ KDH-P, c0G < c0H < c0P. (3.4)
We have a ‘large’ growth factor flux for the first three cases in (3.3) because for each of these
regimes, there is a substantial free component that can diffuse. For example, for the first case, cTH < cTG
and cTH < c0P, we have cG ∼ cTG− cTH. For the boundary and initial conditions of (2.15), this free drug will
clear the system to leading order on the time scale t = O(L2/DGH). However, once the free component
has cleared, the remaining bound component in the bulk will be governed by the fourth regime of (3.3),
and this will clear the system on the long time scale t = O(L2/(εDGH))≫ O(L2/DGH). Similar remarks
apply to the second and third regimes in (3.3). Hence, if the matrix is prepared with KbH,KbP ≫ 1, and
if our governing model is appropriate, then we are assured that at least a fraction of the growth factor
will release on the slow time scale t = O(L2/(εDGH)). Furthermore, we predict that almost all of the
growth factor will release slowly if the matrix is prepared with c0H/c0G > 1 and c0P/c0H > 1; notice that it
is not required that these fractions be large; see Figure 4. However, we should caution that if there is
a substantial component of free peptide (which is not included in the model described here), then there
can still be a significant amount of free growth factor that can release on a fast diffusion time scale.
The two stage release behaviour just described has been observed in experiments (see Section 4),
where one sometimes sees a proportion of the growth factor releasing quickly over a period of some
days (which could correspond to free growth factor releasing on a diffusion time scale) followed by
much slower release of the remaining fraction (which could correspond to a strongly retained bound
component releasing on a longer time scale such as that described above).
Incorporating free peptide in the analysis
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We now consider the case where a substantial fraction of the peptide remains free and competes with
the covalently bound peptide for free heparin. We assume that heparin bound to free peptide has the
same binding behaviour for growth factor as free heparin. The essence of our results above carry over,
as we now explain. We suppose that the conditions (3.4) hold, and that the ratio of peptide covalently
attached to the fibrin, r, has been quantified. Then the concentration of cross-linked peptide in the
system is rc0P, and since c0P > c0H, the initial concentration of heparin that is bound to cross-linked peptide
is, to leading order, rc0H. Since in turn c0H > c0G, the initial concentration of growth factor trapped by the
delivery system is, to leading order, rc0G. It follows that a fraction (1− r) approximately of the growth
factor will diffuse out of the system over a diffusion time scale. Hence, the final recommendation, which
we add to (3.4), is that c0G should be chosen so that rc0G is sufficiently large for the therapy to be effective.
3.1.2 Numerical Solutions Two different procedures were used to numerically integrate the initial
boundary value problem (2.15). In one method, simple explicit time-stepping was used to update the
values of cTG, cTH, with the other quantities being then updated using (A.1). Centred difference approxi-
mations were used for cGxx, cHxx, cGHxx, and the no-flux conditions on x = 0 were handled by introducing
a fictitious line in the usual way. In the other method, the system was numerically integrated using the
MAPLE command pdsolve/numeric, which is based on a centred implict finite difference scheme.
Good agreement was obtained between the two schemes and with known analytical results.
In Figure 5, we display numerical profiles for the fraction of total growth factor that has released
from the system as a function of time over a period of a fortnight. Four of the five release profiles
displayed in Figure 5 (a) correspond to the case KbH,KbP ≫ 1, the regime we recommend for matrix
preparation. The other parameter values are all O(1), and can be found either on the figure or in its
caption. The fifth profile, the top curve in the figure, corresponds to the case of no drug delivery system,
and has been included for comparison. In this case, all of the growth factor is free in the gel, and its
concentration is governed by the usual linear diffusion equation (see Section 3.2.1). The other four
curves correspond to the four asymptotic regimes identified in the previous Section. We observe for
these that the growth factor release rate becomes slow after a period of appproximately a day, and this
is easily interpreted. The fast initial release phase corresponds to the rapid out-diffusion of free growth
factor on a diffusion time scale; notice that this period coincides (tellingly) with the period over which
the growth factor releases when there is no delivery system. Once the free component has substantially
exited the system, the remaining bound fraction releases slowly over a long time scale, as previously
explained. In all cases, the numerical results are consistent with the asymptotic predictions.
In Figure 5 (b), we display numerical solutions to (2.15) for KbP,ηH/G ≫ 1, and for various values
of KbH. These parameters correspond to the heparin being strongly retained by the peptide, and the
initial concentration of heparin greatly exceeding that of the growth factor. However, we see from the
figure that this is not sufficient to guarantee slow release of growth factor. For values KbH = O(1), which
correspond to moderate retention of growth factor, the growth factor will release over a period of some
days. This compares unfavourably with the results displayed in Figure 5 (a) where both KbP and KbH are
large and we have slow release in all cases even though the values for ηH/G there are only O(1).
3.2 Assessing the validity of the model experimentally
The appropriateness of the proposed governing mathematical model may be assessed experimentally for
a particular system by simply omitting components from the polymerization mixture when preparing
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FIG. 5. Numerical solutions of the initial boundary value problem (2.15). We display the predicted fraction of total growth factor
released over a two week period. We use the parameter values D∗G = 6, D∗H = 3, θ = 9× 10−3 , KbP = 3000 throughout. In (a),
KbH = 8000 with various ηH/G, ηH/P values indicated on the curves. In (b), ηH/G = 1000, ηH/P = 1/40 with various KbH values
indicated on the curves.
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the fibrin gels. The governing mathematical model may then reduce considerably, making it easier to
compare its predictions with experimental data and enabling parameter estimation. We suggest that such
simpler systems should be assessed experimentally as a preliminary to consideration of the complete
release system. We consider two such cases, and then make a brief remark concerning the full system.
3.2.1 No heparin If in the preparation of the fibrin matrices, no heparin is added to the fibrinogen
solution, then cH = cGH = cHP = cGHP = 0. The dimensional form for the governing equations reduces to:
∂cG
∂ t = DG
∂ 2cG
∂x2 , (3.5)
∂cG
∂x = 0 on x = 0, cG = 0 on x = L, cG = c
0
G at t = 0,
and this is easily solved by separating variables (Crank (1975)) to obtain:
cG(x, t) =
4c0G
pi
∞
∑
n=1
(−1)n+1
2n− 1
exp
(
−(2n− 1)2pi2DGt
4L2
)
cos
(
(2n− 1)pix
2L
)
.
The total amount of growth factor released from the fibrin matrix by time t is then given by:
M(t) = Lc0G−
L∫
0
cG(x, t)dx,
from which it follows that the fraction of the available growth factor released by time t is:
M(t)
M(∞)
= 1− 8
pi2
∞
∑
n=1
1
(2n− 1)2
exp
(
−(2n− 1)2pi2DGt
4L2
)
. (3.6)
This expression contains only one unknown parameter, DG, and it predicts that the growth factor should
release on the time scale t =O(L2/DG), which for the matrices described here and typical growth factors
corresponds to a period of some days. We suggest a four day release experiment and at least three data
points per day for the fraction of growth factor released. This release data may then be compared with
(3.6). If there is a poor match between the experimental and theoretical profiles, or if one finds that
an unreasonable value for DG must be used to obtain an acceptable fit, then the appropriateness of the
model for the delivery system of interest is called into question. It may be that some other process not
incorporated in the modelling is significantly affecting the release behaviour.
3.2.2 No growth factor and peptide If both growth factor and peptide are omitted from the polymer-
ization mixture, then cG = cP = cGH = cHP = cGHP = 0. The only surviving species in the model is free
heparin, and its concentration is governed by an initial boundary value problem identical in structure to
(3.5); simply substitute G with H in (3.5) and (3.6). We now suggest a four day release experiment for
the heparin with at least three data points per day for the fraction of heparin released. The experimen-
tal and theoretical release results may then be compared, providing a second test of the validity of the
model. If the correspondence between theory and experiment is good, then the heparin diffusivity DH
is estimated (of course the value obtained must be consistent with previous estimates; it must have the
correct order of magnitude).
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3.2.3 The full system If the model passes the tests set for it in the previous two subsections, one
may proceed to preparing the matrix with all components included. If the matrix is prepared in accor-
dance with the recommendations (3.4), one should experimentally observe the growth factor release rate
become slow after a period of a few days if the model is valid.
4. Comparison with experimental data
We now compare the theoretical release profiles generated by the model with in vitro experimental
release data. For experimental data where there is no delivery system or no heparin, we make the com-
parison with the model for all times using the analytical expression (3.6). However, for experimental
data where the full delivery system is present, we do not attempt to compare the model results with
experimental data in the first two days of release since free peptide may play a significant role in this
period, and the model does not track the concentration of this species. In fact, to incorporate the effect of
free peptide would require the inclusion of three more species in the model: free peptide, free peptide-
heparin complex, and free peptide-heparin-growth factor complex; see Wood et al. (2007). This would
add three reaction-diffusion equations to the governing mathematical model, and would complicate the
analysis considerably. However, after a period of some days, all of these species should have substan-
tially diffused out of the system since there is no mechanism to replenish them (the covalently bound
peptide does not dissociate), and the species that then remain do form part of the model described here.
We should say that it is not difficult to fit the model results with complete release profiles that include
the first few days, but this would require the selection of parameters in the model that are not compat-
ible with the experimental conditions. The numerical solutions displayed in Figure 5 (a) do have the
qualitative character of many experimental profiles.
In selecting parameter values for the model, we use wherever possible the values used in the exper-
iments. We always use the same heparin to growth factor ratio ηH/G and heparin to peptide ratio ηH/P as
used in the experiments. Where estimates for the diffusivities can be found, either in the experimental
paper in question, or elsewhere, we use them. Where a value for DG is not available, we estimate it
by fitting an experimental profile for no delivery system to the corresponding theoretical release pro-
file (3.6). For DGH, we then select a value which has order of magnitude 10−5 cm2/min, and which is
such that DGH < DG,DH. The values for KbP = c0P/KDH-P are calculated using the given values for c0P and
KDH-P = 8.67× 10−8 M. This is probably an over-estimate since we are beginning our simulation after
day two and unbound peptide will have been lost, reducing the value for c0P. A similar remark applies to
the values of c0G and c0H. However, the values for KbP are of the order of thousands, and adjusting them
by a factor of two or so will have very little effect on the resulting profiles. The selection of appropriate
values for KbH = c0H/KDG-H is a much more delicate issue though because its values range considerably
in the experiments and the behaviour is usually strongly dependent on this value. Unfortunately, both
numbers involved in the calculation of KbH are uncertain here since c0H needs to be reduced as explained
above and only order of magnitude estimates are available for KDG-H. Hence, we use KbH as a fitting pa-
rameter, but insist that it has the same order of magnitude as c0H/KDG-H where c0H is the value given in the
experiment and KDG-H is the order of magnitude estimate for this dissociation constant.
We have chosen to compare the model results with experimental data drawn from three studies: (a)
Taylor et al. (2004), (b) Wood et al. (2007), and (c) Wood et al. (2008); we shall subsequently refer to
these as (a),(b),(c), and this labelling has also been used in Figure 6 where the comparison between the
model and the experimental data is given. In (a), (b), (c) the growth factors used are NT-3, NGF and
GDNF, respectively. In Figure 6, we also display in each case the solution (3.6) with the appropriate
value for DG, which is the theoretical prediction when there is no delivery system or no heparin. In
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Figure 6 (a), we display experimental data with KbH ∼ 1 and KbH ∼ 5, but we do not attempt to fit this
data other than to comment that it follows quite closely the behaviour of the solution (3.6).
We note that the correspondence between the model and experimental data is satisfactory in all
cases. It is clear that for KbH ≫ 1, the experimental release rates becomes slow after a few days, which
is consistent with the theoretical prediction. For O(1) values of KbH (Figure 6 (a)), the experimental
realease rates are comparable to that for no delivery system. The experimental release profiles for data
corresponding to no delivery system or no heparin are adequately described by (3.6).
5. Discussion
We summarise our results.
• We have shown that for conditions of typical interest, the governing mathematical model may be
reduced to a system of just two partial differential equations, and that the release behaviour is
frequently dominated by the values of two non-dimensional parameters. If the model is valid for
a particular system, there will usually be slow passive release of at least a fraction of the growth
factor if the fibrin matrices are prepared with the concentration of crosslinked peptide greatly
exceeding the dissociation constant of heparin from peptide, and the concentration of heparin
greatly exceeding the dissociation constant of growth factor from heparin. It is noteworthy that
these criteria do not preclude slow release for growth factors that bind heparin with low affinity.
We also note the value of having reliable estimates for the two dissociation constants in the system.
• It is experimentally convenient to vary the ratios of heparin to growth factor and of heparin to
peptide in the polymerisation mixture for the gels to determine optimal conditions for slow passive
release. However, these ratios are not usually the key parameters, and where this strategy does
result in slow release, we have found that it is because the binding constants have strayed into the
regime referred to in the point immediately above. Our results indicate that the ratios of heparin
to growth factor and of heparin to peptide in the polymerisation mixture need neither be large nor
small for slow release.
• For the first time, theoretical release profiles generated by the model are compared directly with
in vitro experimental data. It is found that once the free components have cleared the system,
the correspondence between experimental and theoretical results is satisfactory. In particular, our
predictions concerning conditions that will give rise to slow passive release are confirmed.
• It may be possible to partially unpick the system experimentally by simply omitting components
in the polymerization mixture for the fibrin gels. For example, if heparin is omitted from the
polymerization mixture, the governing mathematical model reduces to a standard linear diffusion
equation for the growth factor, and theoretical predictions may then be readily compared with
experimental data to help validate the model and estimate a diffusivity; see Section 3.2.
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Appendix
Species concentrations in terms of total growth factor and total heparin
Solving the six algebraic expressions (2.10)6, (2.13)1, (2.14) for the concentrations of the six species
cG, cH, cGH, cP, cHP, cGHP in terms of the total concentration of growth factor, cTG, and heparin, cTH, gives:
cG(c
T
G,c
T
H) =
cTG−ηH/GcTH− ηH/GKbH +
√(
cTG−ηH/GcTH− ηH/GKbH
)2
+
4ηH/GcTG
KbH
2
,
cP(c
T
H) =
1− 1KbP −ηH/Pc
T
H +
√(
ηH/PcTH− 1− 1KbP
)2
+
4ηH/PcTH
KbP
2
,
cGH(c
T
G,c
T
H) =
ηH/G
ηH/P (1− cP(c
T
H))
{
1
KbPcP(cTH)
+ 1
1+ KbHθcG(c
T
G ,c
T
H)
ηH/G(1+θ )
}
−
ηH/G(cTG−cG(cTG,cTH))
KbHcG(cTG,cTH))
1+
KbPcP(cTH)
1+θ
1+ KbHθcG(c
T
G ,c
T
H)
ηH/G(1+θ )
,
(A.1)
cGHP(c
T
G,c
T
H) = c
T
G− cG(c
T
G,c
T
H)− cGH(c
T
G,c
T
H),
cHP(c
T
G,c
T
H) =
1
ηH/P (1− cP(c
T
H))−
KbPcGH(cTG,cTH)cP(cTH)
ηH/G(1+θ)
1+ KbHcG(c
T
G,c
T
H)θ
ηH/G(1+θ)
,
cH(c
T
G,c
T
H) = c
T
H− cHP(c
T
G,c
T
H)− (cGH(c
T
G,c
T
H)+ cGHP(c
T
G,c
T
H))/ηH/G.
Hence, in the model considered here, it is sufficient to solve for cTG and cTH.
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TABLE 1 The data used to generate the theoretical curves in Figure 6. Unmarked data is taken from the
paper referred to in its column. The markings on the remaining data are explained below the table.
Figure 6 (a) Figure 6 (b) Figure 6 (c)
Symbol NT-3 (Taylor et al. (2004)) NGF (Wood et al. (2007)) GDNF (Wood et al. (2008)) Units
DG 2.5× 10−5
(a) 9.7× 10−5 2.0× 10−5(a) cm2/min
DH 3.0× 10−5
(b) 9.1× 10−5 3.0× 10−5(b) cm2/min
DGH 1.0× 10−5
(c) 7.5× 10−5 1.5× 10−5(a) cm2/min
KDG-H 1.5× 10−7
(a) 0.33× 10−7(a) 1.25× 10−7(a) M
KDH-P 8.67× 10−8
(d) 8.67× 10−8(d) 8.67× 10−8(d) M
c0P 2.3× 10−4 2.5× 10−4 2.5× 10−4 M
c0G 7.4× 10−9 7.4× 10−9 3.1× 10−9 M
(a) Estimated from data in Taylor et al. (2004); Wood et al. (2007, 2008).
(b) Gaigalas et al. (1995).
(c) Saltzman et al. (1994).
(d) KR = 78 min−1 (Olson et al. (1981)) and KF = 9.0×108 M−1min−1 (Tyler-Cross et al. (1994, 1996); Kridel et al. (1996)).
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FIG. 6. Comparison of experimental and theoretical release profiles. The curves are theoretical and the symbols are experimental.
In the figure, (a) has data for NT-3 taken from Taylor et al. (2004), (b) has data for NGF taken from Wood et al. (2007), and (c)
has data for GDNF taken from Wood et al. (2008). The values of KbH used to generate the theoretical curves are given on them
and the remaining parameters used can be found in Table 1 of the Appendix. In (a), two approximate KbH values for experimental
data are also given.
